37 results
D
NLSP
NLS Pharmaceutics Ltd
3 Apr 24
$1.75 mm in equity / options / securities to be acquired, sold $1.75 mm, 2 investors
4:01pm
require offering materials under this undertaking or otherwise and can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
6-K
EX-10.1
NLSP
NLS Pharmaceutics Ltd
21 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
5:14pm
) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus … , contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture
6-K
EX-99.2
NLSP
NLS Pharmaceutics Ltd
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
as well as expenses related to lab supplies, materials and facility costs.
Clinical trial costs are a major component of research and development expenses
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
16 Nov 23
Report of Foreign Private Issuer
4:05pm
all reasonable efforts to arrange for the confidential treatment of the materials and information so disclosed.
Each Party may use any Confidential
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
25 Oct 23
Report of Foreign Private Issuer
9:02am
efforts to arrange for the confidential treatment of the materials and information so disclosed.
Each Party may use any Confidential Information
6-K
EX-99.1
q5j5hffdnkhh
20 Jul 23
Report of Foreign Private Issuer
4:06pm
6-K
EX-99.3
thnywh
3 Jul 23
NLS Pharmaceutics Releases the Results from its Annual General Meeting
1:22pm
D
omeadj4te6 3bnvikgs8
21 Dec 22
$30.00 mm in equity / options / securities to be acquired, sold $10.00 mm, 4 investors
4:01pm
6-K
EX-99.3
gr3s42tg09i5 n5rv
8 Dec 22
Report of Foreign Private Issuer
4:30pm
D
7odol7dqvgbcfv0a4
14 Oct 22
$4.00 mm in equity / options, sold $4.00 mm, 5 investors
6:07am
6-K
EX-99.2
3slyd8ebweb zmt
11 Oct 22
Unaudited Interim Condensed Financial Statements
5:20pm
6-K
EX-99.2
9hm weq9ww
3 Oct 22
Report of Foreign Private Issuer
8:51am
6-K
EX-10.1
qp7gb2 n1yfoszn
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
6-K
EX-10.2
583mtto8 93f72b3pb0a
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
6-K
EX-1.1
pwz4vp 02zy
4 Mar 22
Report of Foreign Private Issuer
4:02pm
6-K
EX-99.2
nbgv353vil1 cp206z
28 Sep 21
Unaudited Interim Condensed Financial Statements
4:02pm
6-K
EX-99.1
75qjctqt
28 Sep 21
Standby Equity Distribution Agreement
8:30am
20-F
EX-4.6
fuff5 om0bjzopt
14 May 21
Annual report (foreign)
5:05pm